Levosimendan
Levosimendan is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
88 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 6 | 7 | 14 | 5 | 32 |
| Cardiogenic shock | D012770 | R57.0 | — | 1 | 3 | 1 | 3 | 7 | |
| Low cardiac output | D002303 | 1 | 4 | 2 | 1 | 1 | 7 | ||
| Septic shock | D012772 | A48.3 | — | 2 | 1 | 1 | 2 | 5 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | 1 | 1 | 1 | 3 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | 2 | — | 2 |
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | — | 1 | 1 | 2 |
| St elevation myocardial infarction | D000072657 | — | — | 1 | 1 | — | 2 | ||
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | 1 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | 1 | 1 | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular dysfunction | D018487 | — | — | 1 | — | 3 | 4 | ||
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 2 | — | — | 2 | |
| Cardio-renal syndrome | D059347 | — | — | 1 | — | 1 | 2 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | — | 2 | — | — | 2 |
| Heart disease risk factors | D000082742 | — | — | 1 | — | — | 1 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | — | — | — | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 1 | 2 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | — | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 2 | 2 |
| Right ventricular dysfunction | D018497 | — | — | — | — | 1 | 1 | ||
| Femoral fractures | D005264 | S72 | — | — | — | — | 1 | 1 | |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 1 | 1 |
| Physiologic monitoring | D008991 | — | — | — | — | 1 | 1 | ||
| Sepsis | D018805 | A41.9 | — | — | — | — | 1 | 1 | |
| Cardiopulmonary bypass | D002315 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LEVOSIMENDAN |
| INN | levosimendan |
| Description | Levosimendan is a hydrazone, a pyridazinone and a nitrile. It has a role as a vasodilator agent, an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor, a cardiotonic drug and an anti-arrhythmia drug. |
| Classification | Small molecule |
| Drug class | positive inotropic agents (pimobendan type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 141505-33-1 |
| RxCUI | 73107 |
| ChEMBL ID | CHEMBL2051955 |
| ChEBI ID | 50567 |
| PubChem CID | 3033825 |
| DrugBank | DB00922 |
| UNII ID | C6T4514L4E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,867 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
114 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more